News in other languages: Nicox SA

16/09	Nicox va présenter des données sur le NCX 470 lors d'un congrès
16/09	Nicox : Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt
11/09	Bourse : Alstom et Airbus engrangent de gros contrats, Oracle rassure
11/09	Nicox obtient une autorisation en Chine
11/09	Very bad trip en bourse ?

More news

Managers and Directors: Nicox SA

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Emmet Purtill PRN	Corporate Officer/Principal	-	01/01/2006

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	+0.80%	+24.41%	-5.67%	-22.26%	33.96M
MERCK & CO., INC.	-0.19%	+2.04%	+80.19%	+36.80%	362B
MERCK KGAA	-1.22%	-1.22%	+19.95%	-17.53%	64.74B
HALOZYME THERAPEUTICS, INC.	+2.53%	+4.90%	+44.52%	+182.75%	12.76B
KYOWA KIRIN CO., LTD.	-0.29%	+2.94%	-4.00%	-16.51%	7.53B
SK BIOPHARMACEUTICALS CO., LTD.	-1.89%	-2.14%	-31.54%	-13.67%	4.38B
YUHAN CORPORATION	-2.06%	-4.41%	-36.00%	+2.04%	4.08B
BETTA PHARMACEUTICALS CO., LTD.	+1.48%	+3.64%	-29.60%	-14.61%	2.96B
SUPERNUS PHARMACEUTICALS, INC.	-2.14%	+0.86%	-8.77%	+47.68%	2.44B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.41%	+1.15%	-23.58%	-31.98%	1.93B
Average	-0.47%	+0.50%	+0.55%	+15.27%	51.46B
Weighted average by Cap.	-0.29%	+1.57%	+65.73%	+31.02%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
18/09/26	EUR 0.3160	+0.80%
17/09/26	EUR 0.3135	+13.18%
16/09/26	EUR 0.2770	-1.60%
15/09/26	EUR 0.2815	+14.90%
14/09/26	EUR 0.2450	-3.54%

Delayed Quote Börse Stuttgart

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3360EUR

Average target price

1.000EUR

Spread / Average Target

+197.62%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Börse Stuttgart 05:56:12 19/09/26 am AEST			5-day change	1st Jan Change
0.3160 ^EUR	+0.80%		+24.41%	+14.49%

16/09	Nicox to present NCX 470 data at a conference
11/09	Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review	MT

Market Cap	29.61M 33.96M 27.96M 25.39M 47.57M 3.26B 47.77M 335M 129M 1.66B 128M 125M 5.33B	P/E 2026 *	-6.72x	P/E 2027 *	16.8x
Enterprise Value	29.61M 33.96M 27.96M 25.39M 47.57M 3.26B 47.77M 335M 129M 1.66B 128M 125M 5.33B	EV / Sales 2026 *	9.87x	EV / Sales 2027 *	2.96x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALCOX	Real-time
Börse Stuttgart	NXOA	Delayed
CBOE	COXp	Real-time
Deutsche Boerse AG	NXOA	Delayed
CBOE	0RCQ	Real-time
Boerse Muenchen	NXOA	Real-time

16/09	Nicox to present NCX 470 data at a conference
11/09	Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review	MT
11/09	Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China	CI
11/09	Nicox wins regulatory acceptance in China
02/09	Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor	CI
27/08	The FDA will issue its decision on Nicox's NCX 470 by the end of next April
27/08	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027	MT
27/08	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470	CI
10/08	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China	CI
10/08	Nicox Partner Files China Drug Application for NCX 470 Eye Drop	MT
10/08	A Nicox partner has cleared an important milestone in China
01/07	Nicox Submits NCX 470 New Drug Application In The United States	CI
01/07	Nicox files U.S. marketing approval application

Nicox SA Stock Börse Stuttgart

Stocks

NXOA

FR0013018124

Pharmaceuticals

Valuation: Nicox SA

Chart: Nicox SA

Latest news: Nicox SA

Press Releases: Nicox SA

News in other languages: Nicox SA

Quotes and Performance

Price Extremes

Managers and Directors: Nicox SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

16/09	Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026	GL
11/09	Nicox Announces NCX 470 NDA in China Accepted for Review	GL
02/09	Nicox Announces Extension of Cash Runway	GL
27/08	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma	GL
10/08	Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension	GL

1 week	+24.41%
Current month	-6.78%
1 month	-5.11%
3 months	-5.67%
6 months	-16.73%
Current year	+14.49%

1 week	0.24	0.34
1 month	0.22	0.39
3 years	0.11	0.7
5 years	0.11	3.54
10 years	0.11	13.31

	2026 *	2027 *
Net sales	3M 3.44M 2.83M 2.57M 4.82M 330M 4.84M 33.93M 13.09M 168M 12.92M 12.64M 540M	10M 11.47M 9.44M 8.57M 16.06M 1.1B 16.13M 113M 43.65M 559M 43.08M 42.12M 1.8B
Net income	-5M -5.73M -4.72M -4.29M -8.03M -550M -8.07M -56.55M -21.82M -280M -21.54M -21.06M -900M	2M 2.29M 1.89M 1.71M 3.21M 220M 3.23M 22.62M 8.73M 112M 8.62M 8.42M 360M
Net Debt	-	-